Introduction
The distribution and activity of a drug in the body is largely a function of its physicochemical properties. An alternative approach to affect the intrinsic biodistribution of antibacterial drugs is provided by their encapsulation in colloidal carriers, which hide and protect the drug molecules from peripheral degradation, delivering it to an inaccessible target site, possibly also in a controlled and predictable manner [1] [2] [3] .
In this perspective of targeting, liposomes have been the most studied systems.
They possess the typical features of colloidal carriers, are biodegradable and biocompatible, and their composition and properties can be finely modulated to improve their interaction with and/or penetration through cell membranes [4, 5] .
Liposomes have shown a particular validity in the treatment of infections by intracellular bacteria [6] [7] [8] .
Scarce cell interaction and uptake is at the basis of the limited potency of many antibiotics against infections. Microorganisms in infected tissues are further protected by various biological structures in their cell or around the infection.
For instance, Gram-negative bacteria possess an outer membrane (OM), rich in lipopolysaccharide (LPS) and proteins, that covers and protects the internal peptidoglycan wall, by which it is separated by an aqueous periplasmic space [9] . Permeation through the OM is governed by porins, water-filled open channels that allow the movement of hydrophilic molecules across the Page 5 of 32 A c c e p t e d M a n u s c r i p t 5 membrane. The properties of porins vary considerably among wild-type bacterial species, and their functional structure, size and expression (and hence the ability of an antibiotic to be taken up by a bacterial cell) may change in strains with acquired resistance [9, 10] . Antibacterial drugs can cross the OM by two main pathways: hydrophobic compounds enter by a passive route, whereas hydrophilic antibiotics diffuse through porin channels. The lipid and protein compositions of the OM have a strong influence on the sensitivity of bacterial cells to antibiotics, and intrinsic drug resistance involving modifications of these macromolecules has been often reported [9, [11] [12] [13] .
For instance, alterations in the composition and size of porins and/or in the LPS of the OM have been shown to alter the sensitivity profiles of bacteria to some fluoroquinolones [14] , -lactam antibiotics [10] , erythromycin and even some of the more recent macrolides [15] .
Glycopeptides are tricyclic macromolecular peptides with a complex chemical structure and a high molecular weight (1450-1500 Da). Because of their high molecular weight and size, they are unable to pass through porins in the OM to reach the cell wall area, which represents their site of action; therefore, Gramnegative bacteria are intrinsically resistant to this class of antibiotics [16] . M a n u s c r i p t 6 Among the glycopeptides, vancomycin (VAN) is largely used in the clinical treatment of severe infections caused by multiresistant Gram-positive bacteria such as staphylococci, enterococci, diphtheroid bacilli and clostridia. VAN inhibits the synthesis of peptidoglycan, the major component of the bacterial cell wall. Its mechanism of action is unusual since it binds with its peptide portion the terminal D-alanine-D-alanyl peptide portion of the peptidoglycan precursor.
This mechanism of action does not readily permit mutation to resistance [17, 18] .
Encapsulation into or association of antibiotics with colloidal carriers can effectively improve their interaction with pathogenic microorganisms. Among these carriers, liposomes are vesicular systems mainly formed by amphipathic phospholipids structured in ordered bilayers, with aqueous spaces inside that allow hosting of hydrophilic molecules. Their nature and structure resemble the cell membrane, thus opening the potentiality for an efficacious interaction between these carriers and cells. Such interaction has been typically classified into four processes, namely adsorption, endocytosis, lipid exchange and fusion [19] . The latter phenomenon has been studied in detail by many authors because it offers the possibility for introducing drugs inside cells more easily [20] [21] [22] .
A peculiar class of phospholipid vesicles has been called 'fusogenic' liposomes.
In general, their bilayers show enhanced ability to interact in their liquid crystalline phase with cell membranes, favouring the reciprocal mixing and A c c e p t e d M a n u s c r i p t 7 release of vesicle content inside cells. Strategies to achieve fusogenic liposomes essentially consist of incorporating in the liposome composition either inactivated Sendai virus envelope components [23] [24] [25] [26] or particular fusogenic lipids that make the liposomes more fluid and able to promote the destabilisation of biological membranes [27] [28] [29] [30] .
In the present work, we have investigated the latter approach by preparing fusogenic liposomes containing VAN, with the aim of extending its antibacterial activity to Gram-negative organisms. In particular, we sought to verify the hypothesis that fusogenic vesicles, up to now essentially studied to improve the penetration of liposomal drugs into mammalian cells, could be applied to the specific condition of Gram-negative bacterial cells, where the presence of the OM resembles the eukaryotic cell membrane.
Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) studies were also performed to visualise the interaction/fusion of these liposomes following incubation with Gram-negative bacterial cells. To determine the amount of VAN loaded in the liposomes, a 0.5 mL fraction of the SUVET was passed through a Sephadex G-50 column (Sigma) (eluent, phosphate buffer solution, pH 7.4) to remove the unencapsulated fraction of the antibiotic. The purified liposome suspension was treated with Triton X-100 (5% w/v), then filtered through 0.22 m pore size 13 mm nylon membrane filters (Whatman International Ltd., Maidstone, UK) and submitted to high-pressure M a n u s c r i p t 11 liquid chromatography to calculate VAN concentration, according to a published analytical method [32] . Drug concentration was expressed either as the entrapment efficiency, corresponding to the percent drug remaining encapsulated in the liposomes with respect to the amount initially added, and as drug loading, i.e. g of VAN per mL of vesicle suspension.
Materials and methods

Microbial strains
Microbiological assay
Minimum inhibitory concentrations (MICs) were determined by the standard broth microdilution method [33] . Each microplate well was filled with 100 L of Müller-Hinton broth and then 100 L of VAN-loaded SUVET suspension (corresponding to 300 g drug/mL and 500 g lipids/mL) or a corresponding volume of unloaded SUVETs as negative control was added. To test the free drug, 100 L of an aqueous solution of VAN (300 g/mL) was used. By following scalar dilutions with the same broth, the different drug concentrations were thus obtained. The control well consisted of 100 L of Müller-Hinton broth.
Five microlitres of each bacterial suspension was then added, suitably diluted with the same broth to achieve a final bacterial concentration of 10 5 colonyforming units/mL in each well. Microplates were then incubated at 37 C for 24 h. Each experiment was performed three times; the measured antibacterial activity was expressed as the MIC range (see Table 1 ). M a n u s c r i p t 
Results
To study the possibility of releasing VAN The MLV suspension was repetitively passed through a 100 nm polycarbonate membrane. The pores of the latter are almost cylindrical, and unilamellar or multilamellar vesicles larger than the pore diameter are reduced in size and lamellarity during passage through the pores, resulting in a final liposome size that corresponds to the mean size of the pores themselves [34] . As a consequence, uniform vesicles were obtained by this method with a mean size of 103.23  2.87 nm and a polydispersity index of 0.037, which indicates a very high particle size homogeneity. A mean entrapment efficiency of 65.8% was registered, corresponding to a VAN concentration of 2.055 mg/mL of liposome suspension.
In the microbiological assay, free VAN was inactive against all of the tested Gram-negative strains (MIC > 512 mg/L). Conversely, when the drug was loaded in the fusogenic DOPE/DPPC/CHEMS SUVETs, remarkable MIC values were measured (Table 1) 
Discussion
The possibility of phospholipid vesicles fusing with the cell membrane has often been claimed at the basis of the success of liposomal formulations. For instance, encapsulation in liposomes allowed sub-MIC concentrations of tobramycin to act against Gram-negative and Gram-positive bacteria [35] .
In this study, a 4:2:4 (mol/mol) DOPE/DPPC/CHEMS lipid mixture, already described in the literature to produce pH-sensitive liposomes [29] , was chosen to prepare small unilamellar liposome vesicles able to interact and fuse with the cell membrane.
Kinetic studies showed that liposomes made of mixture of DOPE with other lipid components, such as oleic acid, distearoylphosphatidylglycerol or CHEMS, release their content into the cytoplasm after a short incubation time with cells [36] [37] [38] [39] . In particular, the association of DOPE with CHEMS has in fact been recognised to impart vesicles a pH-dependent stability that allows selective fusion of liposomes with specific cell components to be achieved [38, 40] . The exact mechanisms by which these liposomes traverse the cytoplasmic membrane barrier are not completely clear. However, it is likely that partial M a n u s c r i p t 16 fusion of vesicle bilayers with the cell membrane causes destabilisation of the latter, facilitating the release of liposome content into the cytoplasm.
The specific role of phosphatidylethanolamine or DOPE can be explained on the basis of the low hydration of these polar head-groups. The presence of DOPE in fact increases the lipophilicity of the liposomal membrane and reduces the energy of interaction among the lipid bilayers. The presence of DPPC was instead required to form stable liposomal bilayers, since the particular structure of DOPE led to an inverted hexagonal phase instead of a lamellar phase when the lipid was used alone [41] .
In the present study, the fusogenic properties of DOPE/DPPC/CHEMS unilamellar vesicles have been exploited with the purpose of releasing the antibiotic not inside cells but specifically in the narrow area of periplasmic space of Gram-negative bacteria. As a consequence, the OM barrier can be bypassed and the antibiotic can operate its molecular activity at the level of the cell wall.
In the microbiological assay, free VAN displayed no activity against all of the tested bacterial strains. When the antibiotic was loaded in non-fusogenic DPPC/CHOL liposomes, no activity was observed against Gram-negative strains. Negative control tests confirmed that unloaded (empty) SUVETs, made both by DPPC/CHOL (non-fusogenic) or DOPE/DPPC/CHEMS (fusogenic),
were also ineffective against the tested bacteria. In a separate experiment, the A c c e p t e d M a n u s c r i p t 17 extemporary addition of VAN to empty fusogenic liposomes, before addition of the suspension to culture wells, also did not produce any inhibitory activity.
However, the drug showed remarkable MIC values when loaded in fusogenic DOPE/DPPC/CHEMS SUVETs (Table 1 ). In particular, the activity shown against A. baumannii is particularly interesting since this microorganism is naturally sensitive to only a few antibiotics [42] . Even the least sensitive strain among those tested in this study, P. aeruginosa, showed an interesting MIC value (50 mg/L). The same order of activity was registered for the two reference ATCC bacterial strains used. Although it should be confirmed by specific assays, it is conceivable that the lower MIC values observed for P. aeruginosa and Klebsiella spp. were due to the production of mucus, which hinders contact with the liposomes.
The obtained in vitro results, however, supported the initial working hypothesis that the fusogenic properties of the chosen (phospho)lipid mixture were able to convey the active compound through the external membrane inside the periplasmic space, where its antibacterial activity can be exerted. TEM analysis has often been used to confirm the interaction of liposomes with the bacterial cell membrane. For example, Omri and colleagues [43, 44] Fig. 2A) , and small or large liposomes fused with the OM of bacteria (Fig. 2B,   arrows ). Also using conventional visualisation (Fig. 3) , the multilayered structure of the cell envelope was visible, with the arrow indicating the fusion of a large liposome with the OM of bacteria, which also appears deformed.
These results reinforce the supposition that the measured in vitro activity was due to a liposome-carried release of antibiotic inside the bacteria cells. Specific experiments with labelled liposomes have been planned to identify the localisation of the encapsulated probe inside bacterial cells after fusion with this kind of liposome. Furthermore, absence of any sign of bacterial cell injuries in M a n u s c r i p t 19 the microscopy analysis suggested that the tested liposome formulation was not cytotoxic.
The present liposomal formulation can be proposed for the local treatment of Gram-negative sustained infective conditions, such as burns where these bacteria have been largely found [46] . It is conceivable that the presence of eukaryotic cells and tissues will affect the selective fusion of these liposomes with the bacterial cells and this must require committed in vitro and in vivo studies. Moreover, in view of systemic use, the described formulation would need suitable tuning, for instance surface modification of liposomes with hydrophilic polymers, to attain a circulation time in the bloodstream long enough to reach the target sites.
However, the reported and somewhat expected results will prompt us to explore the feasibility of these fusogenic liposomes to improve the activity of other antibiotics against resistant microorganisms. A c c e p t e d M a n u s c r i p t Table 1 Minimum inhibitory concentration ranges (mg/L) of VAN 
